CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company's ...
Moderna plans to continue evaluating mRNA-1647 in an ongoing Phase 2 trial for bone marrow transplant patients, where the vaccine could potentially suppress disease associated with CMV reactivation.
Oct 22 (Reuters) - Moderna (MRNA.O), opens new tab said on Wednesday it would stop developing its experimental vaccine to prevent cytomegalovirus, a virus that can cause birth defects, after it failed ...
In a nation where the smartphone rarely leaves the palm, while the TV’s on in the background, new research from Nielsen Consumer & Media View (CMV) reveals Australians are not abandoning traditional ...
Investing.com -- Moderna Inc. (NASDAQ:MRNA) stock fell 5% in after-hours trading Wednesday following the company’s announcement that its cytomegalovirus (CMV) vaccine candidate failed to meet its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback